The two arms of L&TFH are L&T Finance, with its retail, micro-finance and corporate loan portfolio, and L&T Infrastructure Finance.
Merck arm sues Sun over cancer drugSchering Corporation, part of multinational pharma company Merck & Co, and London-based Cancer Research Technology Ltd have sued Sun Pharmaceutical for allegedly infringing patent rights on the world's largest selling brain cancer drug, Temodar.
The Reliance-Anil Dhirubhai Ambani Group (R-ADAG) has picked up a 15 per cent stake for Rs 225 crore (Rs 2.25 billion) in a new international airport coming up at Aranmula in Pathanamthitta district of central Kerala.
Cipla, the largest player in the domestic drug market, could play white knight for Cipla Medpro, South Africa's third-largest drugmaker and a key ally of the Indian company. Cipla is looking to acquire around 25 per cent in the manufacturing division of Cipla Medpro, where it does not hold any stake at present.
With passage of the nuclear liability Bill, the heavy engineering supply chain, led by Bharat Heavy Electricals Ltd (BHEL), Larsen & Toubro (L&T) and Bharat Forge Ltd (BFL), is gearing to take up the challenge ahead.
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
India Inc's bear hug with Russian consumers is getting warmer. From selling marquee cars to liquor, the relationship is heading into the next league -- joint ventures in diverse areas such as petrochemicals, telecom, pharmaceuticals and nanotechnology.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
Piramal Healthcare acquired 4.36 million shares from the open markets through its two promoter companies, PHL Holding Pvt Ltd and Swastik Safe Deposit & Investment.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
Capex plans for the next six months imply a 20 per cent increase in calendar 2010.
The payout rise was higher than that in net profit, which was 21.5 per cent. As a proportion of net profit, the payout was 25.15 per cent, compared to 24.1 per cent in March 2009 and 21.8 per cent in March 2008.
L&T plans to transfer the equity of L&T in their joint ventures with Mitsubishi Heavy Industries into L&T Power through a book transfer, if clauses for the re-tender remain the same, company executives told Business Standard.
Plans to set up an integrated pharma firm in a phased manner.
Mukesh Ambani's Reliance Industries Ltd may be one of the biggest producers of natural gas in the country, but its power foray is likely to be coal or renewable energy based. The company is planning to not only bid for ultra mega power projects but also go in for acquisition of the power plants, said industry sources.
In 2001-02, demand recession had clipped the sales growth rate of corporate India to 2.6 per cent from the double-digit one of the earlier years.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
The Aditya Birla Group has received in-principle approval from the Kerala government to set up a Rs 4,000-crore (Rs 40 billion) IT and Biotech Knowledge Park and a branch of Birla Institute of Technology and Sciences (BITS) at Kozhikode.
Hiring up, rupee hedges in place, but net addition in clients still subdued.
Larsen & Toubro, India's largest engineering, construction and technology company, is aggressively expanding its footprint across various places abroad
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances